Today’s pharmaceutical companies are facing significant challenges in balancing the demands of increasingly complex drug and device development processes with the need to bring products to market rapidly and safely to meet patient needs. Rising customer demands and emerging regulatory mandates are pushing drug developers worldwide to make significant investments in accelerating and improving their R&D and quality control functions. And at the heart of this movement toward safer and faster clinical trials are Contract Research and Manufacturing Organizations (CRMO) that offer specialized services to help drug developers overcome the shrinking timelines and meet regulatory requirements.

Addressing a gap in the market for an all-in-one CRMO partner is Minnesota-based Microbiologics. Brad Goskowicz, Microbiologics Chief Executive Officer, comments, “More often than not, R&D departments are juggling multiple projects simultaneously, making it difficult to meet demanding timelines and strict regulatory requirements. Biopharma researchers can leverage Microbiologics for our extensive biomaterials catalog, high-throughput testing and manufacturing capacity, and our deep microbiology and virology expertise to achieve their goals on-time and on-budget.”

Microbiologics has a proven track record of partnering with biopharmaceutical companies to successfully bring new life-saving anti-infective drugs, vaccines and therapeutics to market. The company’s core focus is to protect the health and safety of people around the world through continuous scientific innovation. With a highly collaborative approach, Microbiologics provides a full range of biomaterial products and laboratory services including antibacterial, antifungal and anti-viral drug testing, assay development, microbial growth and preservation, viral stock production, microbiome research, repository of 100,000+ clinically important microbial and viral strains, consulting services for drug submission and approval, and qualitative and quantitative microbial controls and challenge organisms.